甲状旁腺全切联合自体前臂移植术对肾性甲状旁腺功能亢进的疗效观察与护理

目的探讨甲状旁腺全切联合自体前臂移植术对肾性甲状旁腺功能亢进患者的疗效。方法回顾性分析2018年2～8月我科收治的34例肾性甲状旁腺功能亢进全麻下行甲状旁腺全切联合自体前臂移植术患者,观察其围手术期收缩压、舒张压、甲状旁腺素水平变化情况对比其术前术后脚后跟、膝关节疼痛情况,对其护理进行梳理。结果 34例患者手术后的收缩压(124.97±20.43)mmHg、舒张压(76.44±12.75)mmHg、甲状旁腺素水平(76.30±20.43)pg/mL均显著低于手术前(P0.05)。脚后跟、膝关节疼痛评估术后疼痛评分明显低于术前(P0.05)。结论甲状旁腺全切联合自体前臂移植术对肾性甲状旁腺功能亢进患者的疗效显著,能显著改善患者生活质量,而积极有效的临床护理,能保证手术的成功,减少并发症的发生。     

Fifty shades of graft: How to improve the efficacy of faecal microbiota transplantation for decolonization of antibiotic-resistant bacteria

Background

Spontaneous decolonization of antibiotic-resistant bacteria (ARB) takes time: approximately 25% after 30 days for carbapenem-producing Enterobacteriaceae or extended-spectrum beta-lactamase-producing Enterobacteriaceae. Faecal microbiota transplantation (FMT) has been proposed as a new strategy to promote decolonization in order to reduce the risk of superinfection due to these ARB. This paper discusses the literature on the use of FMT for this indication, and the improvement levers available to promote its efficacy.

Renal cell carcinoma staging: pitfalls,challenges, and updates

Renal cell carcinoma (RCC) is unusual among cancers in that it often grows as a spherical, well‐circumscribed mass. Increasing tumour size influences the pathological pT stage category within pT1 and pT2, with cutoffs of 40, 70 and 100 mm; however, with increasing size also comes a sharp increase in the likelihood of renal sinus or renal vein tributary invasion, such that clear cell RCC rarely reaches 70 mm without invading one of these. To clarify some previous challenges in assigning tumour stage, the American Joint Committee on Cancer 2016 tumor–node–metastasis classification has removed the requirements than vein invasion be recognised grossly and that vein walls contain muscle for the diagnosis of vein invasion. Renal pelvis invasion has also been added as an additional route to pT3a. Multinodularity or finger‐like extensions from a renal mass should be viewed with great suspicion for the possibility of vein or renal sinus invasion, and, as tumour size increases to over 40–50 mm, thorough sampling of the renal sinus interface should always be undertaken. With increasing interest in adjuvant therapy in renal cancer, the pathologist's role in RCC staging will continue to be an important prognostic parameter and a tool for selection of patients for enrolment in clinical trials.